financetom
Business
financetom
/
Business
/
BRIEF-Atlassian Enters Into Definitive Agreement To Acquire DX
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Atlassian Enters Into Definitive Agreement To Acquire DX
Sep 19, 2025 8:20 AM

Sept 18 (Reuters) - Atlassian Corp ( TEAM ):

* ATLASSIAN ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE DX

* ATLASSIAN CORP ( TEAM ) - TO BUY DX FOR $1 BILLION

* ATLASSIAN CORP ( TEAM ) - DEAL DOES NOT AFFECT FISCAL 2027 MARGIN

TARGET

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Mar 11, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Sand Grove Capital Management LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming...
Virtual Technologies Group Announces Acquisition of Vector Tech Group
Virtual Technologies Group Announces Acquisition of Vector Tech Group
Mar 11, 2026
MAUMEE, Ohio, March 3, 2026 /PRNewswire/ -- Virtual Technologies Group (VTG), a leading IT, security, and cloud services firm backed by Jacmel Partners (Jacmel), announced today that it has acquired Vector Tech Group (Vector Tech), a regional provider of customized and integrated IT solutions to businesses and other organizations. Vector Tech will continue to serve its current roster of customers and employees...
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
Mar 11, 2026
Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced its official launch following a period of stealth operations. The company is emerging with a Phase 1b/2a-ready clinical asset and the first close of its Seed financing. As part of its launch, Persevere has acquired the clinical-stage program and related...
Columbia Basin Ice LLC and Oregon Ice LLC Acquire Reddy Ice Assets in the Pacific Northwest
Columbia Basin Ice LLC and Oregon Ice LLC Acquire Reddy Ice Assets in the Pacific Northwest
Mar 11, 2026
Customers Assured of Seamless Service KENNEWICK, Wash., March 3, 2026 /PRNewswire/ -- Columbia Basin Ice LLC, in partnership with Oregon Ice LLC, today announced the successful acquisition of select manufacturing, distribution, and customer assets formerly operated by Reddy Ice across Washington, Oregon, and Idaho. The transaction became effective February 19, 2026, and includes production facilities, transportation equipment, and established customer...
Copyright 2023-2026 - www.financetom.com All Rights Reserved